Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Advanced Cancer × IFL protocol × 90 days × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Colorectal Neoplasms 13 Carcinoma, Renal Cell 3 Uterine Cervical Neoplasms 2 Stomach Neoplasms 2 Squamous Cell Carcinoma of Head and Neck 2 Melanoma 2 Carcinoma, Non-Small-Cell Lung 2 Urinary Bladder Neoplasms 1 Triple Negative Breast Neoplasms 1 Small Cell Lung Carcinoma 1 Prostatic Neoplasms 1 Pancreatic Neoplasms 1 Ovarian Neoplasms 1 Neoplasms 1 Neoplasm Metastasis 1 Lung Neoplasms 1 Kidney Neoplasms 1 Head and Neck Neoplasms 1 Glioblastoma 1 Gastrointestinal Neoplasms 1 Gastroesophageal Adenocarcinoma 1 Esophageal Squamous Cell Carcinoma 1 Esophageal Neoplasms 1 Endometrial Neoplasms 1 Colonic Neoplasms 1 Central Nervous System Neoplasms 1 Carcinoma, Transitional Cell 1 Carcinoma, Squamous Cell 1 Carcinoma, Merkel Cell 1 Breast Neoplasms 1

Interventions

Nivolumab 2 Gemcitabine 2 zaleplon 1 temsirolimus 1 regorafenib 1 Vorinostat 1 Trastuzumab 1 Sirolimus 1 Rehabilitation 1 Paclitaxel 1 Oxaliplatin 1 IFL protocol 1 Everolimus 1 Clinical Trials, Phase IV as Topic 1 Cisplatin 1 Capecitabine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05605509 2026-02-06

RP-6306 in Patients With Advanced Cancer

Canadian Cancer Trials Group

Phase 2 Completed

Advanced Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡